PHD inhibitors upregulate HIF-α and hence EPO (and other HIF target genes),9,12–16 and companies are pursuing PHD inhibitors for treatment of anaemia and other hypoxia related diseases.17–25 Four PHD inhibitors are currently in clinical trials for anaemia treatment.18,25. Here, PDC is linked to glycogen storage disease VI.